- Conditions
- Overactive Bladder (OAB)
- Interventions
- Mirabegron, Tolterodine ER
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 22
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Darifenacin, Tolterodine, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 162 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • San Diego, California + 9 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 106
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- tolterodine extended release
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 896 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 83 more
- Conditions
- Overactive Bladder
- Interventions
- Tolterodine ER, Placebo, Fesoterodine
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 102
- States / cities
- Enterprise, Alabama • Mobile, Alabama • Montgomery, Alabama + 85 more
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Fesoterodine 8 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 80 more
- Conditions
- Overactive Bladder (OAB)
- Interventions
- Wearable neurostimulation system for saphenous nerve stimulation, tolterodine tartrate 4 mg extended release
- Device · Drug
- Lead sponsor
- NinaMED Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Healthy
- Interventions
- Darifenacin, Tolterodine, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 18 more